Lexicon Pharmaceuticals | LXRX - Ebitda


Lexicon Pharmaceuticals reported $-49.48M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Coherus Biosciences USD -44.34M 9.82M Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Illumina USD 332M 12M Sep/2025
Insmed USD -314.19M 31.48M Dec/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 9.52B 389M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD 17.92M 8.17M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Novartis USD 5.88B 290M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Thermo Fisher Scientific USD 3.17B 335M Dec/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024